Nearly a decade after surviving Ebola, two patients in Sierra Leone still carried traces of the virus in the gel inside their eyes.
The finding comes from a study led by Steven Yeh, MD, professor and Stanley M. Truhlsen Jr. Chair of Ophthalmology at the UNMC Truhlsen Eye Institute, published Nov. 18 in The Lancet Microbe. This publication marks the first time Ebola RNA has been described in the vitreous fluid of the eyes of patients, and the longest the virus’s genetic material has been shown to persist anywhere in an immune privileged, or immune sanctuary site, in the body.
“This work expands our understanding of viral RNA persistence over time and how the immune system responds to Ebola virus within the eye,” Dr. Yeh said.
Many Ebola survivors develop uveitis, an inflammation inside the eye that can cause severe vision loss and even blindness, with estimates ranging from 13% to 34% of survivors. Why it lingers has been an open question. In 2015, Dr. Yeh and a team of collaborators identified Ebola virus within the aqueous humor, the fluid in the front chamber of the eye, in an Ebola survivor who developed sight-threatening uveitis. More recent work by Dr. Yeh’s team found no evidence of virus in the aqueous humor at 1.5 to 3 years after follow-up, but animal and lab studies still pointed to the potential for viral persistence in the vitreous fluid, the clear gel that fills the back of the eye.
“While the virus had cleared one compartment of the eye, we thought there was some likelihood it could still remain in the vitreous gel,” Dr. Yeh said.
The team enrolled 25 patients in Sierra Leone who needed retinal surgery: 10 Ebola survivors from the 2013-16 West African outbreak, five household contacts and 10 patients with uveitis and no Ebola history. Surgeons analyzed vitreous fluid to better understand the processes that lead to uveitis. On average, the survivors had surgery about nine years after falling ill.
Ebola virus RNA was detected in two of the 10 survivors. Five showed antibodies against Ebola produced inside the eye itself, an “immune footprint” left by the virus. None of the patients without an Ebola history showed these findings.
“It’s important to recognize the viral RNA detected was inside the eye and not in the tear film. And whether it is capable of infection is unknown, but further studies are certainly needed,” Dr. Yeh said. Still, the study recommends high-level infection prevention and control precautions for surgeons who operate on survivors or health care providers with potential exposure to their eye fluids.
The findings suggest that lingering viral material, and the immune system’s reaction to it, may help drive years of inflammation. They also raise a larger challenge: how to clear a virus from the parts of the body the immune system shields. An Ebola outbreak is ongoing in the Democratic Republic of the Congo, though it involves a different strain than the one studied here, Dr. Yeh said.
“Looking at long-term complications, how they impact quality of life, and proper care paradigms is very much needed, although it’s easy to move on to more urgent issues,” he said. “But patients still deal with these ongoing concerns, and understanding the scientific basis is important. We also want to avoid creating stigma, as Ebola survivors are patients who require ongoing care.”
Getting to this point took more than a decade. Dr. Yeh began working in Sierra Leone in 2015, and COVID-19 delayed the study by two years. Before any samples could be collected, the team had to build a retinal surgical unit with Ministry of Health providers, providing a service that a country of more than 8 million people did not have: surgical retina care. More than 400 patients outside the study have since had retinal surgery through the program.
“From a population basis, another major win is that retinal detachment can be repaired,” he said. “This is a much better alternative for patients than vision loss or blindness, which is truly devastating. These efforts show that answering important scientific questions can be partnered with building infrastructure and capacity for vision health.”